Michelle R. Lopes-Ugolini

Sao Paulo, SP, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Choroidal thickness in active lupus nephritis.

Choroidal thickness in active lupus nephritis.

Journal: Lupus

Published: January 09, 2026

Effect of hydroxychloroquine dose reduction (2-3 mg/kg/day) on lipoprotein levels in stable lupus nephritis: A 12-month randomized controlled longitudinal study.

Effect of hydroxychloroquine dose reduction (2-3 mg/kg/day) on lipoprotein levels in stable lupus nephritis: A 12-month randomized controlled longitudinal study.

Journal: Lupus

Published: December 27, 2025

High- vs. routine-dose vitamin D3 in severe lupus on pulse methylprednisolone: a randomized, double-blind, placebo-controlled clinical trial.

High- vs. routine-dose vitamin D3 in severe lupus on pulse methylprednisolone: a randomized, double-blind, placebo-controlled clinical trial.

Journal: Clinical rheumatology

Published: April 16, 2025

Poor Prognosis of COVID-19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross-Sectional Population Study Of 252 119 Patients.

Poor Prognosis of COVID-19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross-Sectional Population Study Of 252 119 Patients.

Journal: ACR open rheumatology

Published: July 17, 2021

Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases.

Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases.

Journal: PLoS neglected tropical diseases

Published: May 23, 2021

Cognitive dysfunction and serum levels of brain-derived neurotrophic factor (BDNF) in primary anti-phospholipid syndrome (PAPS).

Cognitive dysfunction and serum levels of brain-derived neurotrophic factor (BDNF) in primary anti-phospholipid syndrome (PAPS).

Journal: Rheumatology (Oxford, England)

Published: February 13, 2020

Antiphospholipid syndrome damage index (DIAPS): distinct long-term kinetic in primary antiphospholipid syndrome and antiphospholipid syndrome related to systemic lupus erythematosus.

Antiphospholipid syndrome damage index (DIAPS): distinct long-term kinetic in primary antiphospholipid syndrome and antiphospholipid syndrome related to systemic lupus erythematosus.

Journal: Lupus

Published: January 29, 2020

Short- and Long-Term Outcome of Systemic Lupus Erythematosus Peripheral Neuropathy: Bimodal Pattern of Onset and Treatment Response.

Short- and Long-Term Outcome of Systemic Lupus Erythematosus Peripheral Neuropathy: Bimodal Pattern of Onset and Treatment Response.

Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

Published: October 26, 2019

Late-onset biopsy-proven lupus nephritis without other associated autoimmune diseases: severity and long-term outcome.

Late-onset biopsy-proven lupus nephritis without other associated autoimmune diseases: severity and long-term outcome.

Journal: Lupus

Published: November 17, 2018

Effectiveness of renoprotective approaches for persistent proteinuria in lupus nephritis: more than just immunosuppression.

Effectiveness of renoprotective approaches for persistent proteinuria in lupus nephritis: more than just immunosuppression.

Journal: Lupus

Published: November 06, 2018

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR).

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR).

Journal: Annals of the rheumatic diseases

Published: April 02, 2018

Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management.

Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management.

Journal: Seminars in arthritis and rheumatism

Published: November 29, 2017

Showing 1-12 of 14

Last Updated: 09/26/2026